![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced...
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.76 | 1.75803839926 | 43.23 | 47.805 | 42.2 | 494126 | 45.26840088 | CS |
4 | 2.32 | 5.56755459563 | 41.67 | 48.9399 | 37.72 | 538697 | 43.11154236 | CS |
12 | -19.99 | -31.2441387934 | 63.98 | 65.6 | 37.72 | 755421 | 47.03565378 | CS |
26 | 34.22 | 350.255885363 | 9.77 | 65.6 | 7.79 | 852272 | 45.80607653 | CS |
52 | 30.79 | 233.257575758 | 13.2 | 65.6 | 5.65 | 472010 | 41.87792617 | CS |
156 | 13.78 | 45.6140350877 | 30.21 | 65.6 | 5.65 | 227652 | 34.38944925 | CS |
260 | 9.99 | 29.3823529412 | 34 | 65.6 | 5.65 | 232010 | 33.86331547 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions